Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on February 18, 2021. The report discloses compensatory arrangements for certain executive officers approved by the Compensation Committee and Board of Directors on the same date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and does not contain financial performance data.
Material Changes
The material event reported is the approval of new stock option awards for three executive officers under the Company's 2012 Equity Incentive Plan. No other material changes to the company's financial position or operations are disclosed in this document.
Management Commentary and Unusual Items
The filing details the specific terms of the equity awards granted on February 18, 2021:
- Recipients: Dr. Alan Joslyn (CEO), Mr. Michael Sullivan (CFO), and Dr. Martin Handfield (SVP of Discovery Research).
- Grant Size: 400,000 shares for the CEO, 250,000 shares for the CFO, and 220,000 shares for the SVP.
- Exercise Price: $1.20 per share, based on the closing price on the grant date.
- Vesting Schedule: Time-based vesting in equal annual installments over three years (first, second, and third anniversaries of the grant date).
- Conditions: Awards include standard terms, including earlier vesting upon a change in control.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2012 Equity Incentive Plan to assess remaining capacity for future grants.
- Confirm the current market price of OGEN stock relative to the $1.20 exercise price to evaluate the intrinsic value of the awards.
- Review the company's most recent 10-K or 10-Q for comprehensive financial metrics, as this 8-K does not contain them.
- Check for any subsequent filings regarding the vesting status or exercise of these specific options.